ATE258685T1 - Makromolekulare mikropartikel und verfahren zur ihrer herstellung - Google Patents

Makromolekulare mikropartikel und verfahren zur ihrer herstellung

Info

Publication number
ATE258685T1
ATE258685T1 AT97112821T AT97112821T ATE258685T1 AT E258685 T1 ATE258685 T1 AT E258685T1 AT 97112821 T AT97112821 T AT 97112821T AT 97112821 T AT97112821 T AT 97112821T AT E258685 T1 ATE258685 T1 AT E258685T1
Authority
AT
Austria
Prior art keywords
microparticles
production
dehydrating agent
microparticle composition
macromolecular
Prior art date
Application number
AT97112821T
Other languages
English (en)
Inventor
James E Woiszwillo
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Application granted granted Critical
Publication of ATE258685T1 publication Critical patent/ATE258685T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AT97112821T 1993-03-09 1994-03-04 Makromolekulare mikropartikel und verfahren zur ihrer herstellung ATE258685T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2823793A 1993-03-09 1993-03-09

Publications (1)

Publication Number Publication Date
ATE258685T1 true ATE258685T1 (de) 2004-02-15

Family

ID=21842313

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97112821T ATE258685T1 (de) 1993-03-09 1994-03-04 Makromolekulare mikropartikel und verfahren zur ihrer herstellung
AT94910826T ATE163230T1 (de) 1993-03-09 1994-03-04 Makromolekulare mikropartikel und verfahren zu ihrer herstellung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT94910826T ATE163230T1 (de) 1993-03-09 1994-03-04 Makromolekulare mikropartikel und verfahren zu ihrer herstellung

Country Status (11)

Country Link
US (1) US5578709A (de)
EP (2) EP0688429B1 (de)
JP (5) JPH08507806A (de)
AT (2) ATE258685T1 (de)
AU (1) AU6358594A (de)
CA (1) CA2157793C (de)
DE (2) DE69433523T2 (de)
DK (1) DK0809110T3 (de)
ES (2) ES2215207T3 (de)
PT (1) PT809110E (de)
WO (1) WO1994020856A1 (de)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
WO1996020012A2 (en) * 1994-12-23 1996-07-04 Middlesex Sciences, Inc. Methods for preparing and purifying macromolecular conjugates
WO1997035561A1 (en) 1996-03-28 1997-10-02 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved liposome compositions
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
EP1059943B1 (de) 1998-03-06 2004-12-01 Biosepra Medical Inc. Implantierbare partikel zur erhöhung des gewebevolumens und zur behandlung von gastroösophagalreflux, inkontinenz und hautfalten
US6660301B1 (en) 1998-03-06 2003-12-09 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
US20070009605A1 (en) * 1998-07-23 2007-01-11 Ignatious Francis X Encapsulation of water soluble peptides
WO2000004916A1 (en) * 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
US6270700B1 (en) 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides
FR2784580B1 (fr) 1998-10-16 2004-06-25 Biosepra Inc Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci
EP1074248A1 (de) * 1999-07-08 2001-02-07 Arnold Hilgers Verabreichungssystem für biologisches Material
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6822086B1 (en) 1999-08-09 2004-11-23 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
EP1267946A4 (de) 2000-02-28 2008-07-02 Genesegues Inc Nanokapsel-einkapselungs-system und verfahren
US6436424B1 (en) 2000-03-20 2002-08-20 Biosphere Medical, Inc. Injectable and swellable microspheres for dermal augmentation
US7338657B2 (en) * 2001-03-15 2008-03-04 Biosphere Medical, Inc. Injectable microspheres for tissue construction
WO2001070289A2 (en) 2000-03-20 2001-09-27 Biosphere Medical, Inc. Injectable and swellable microspheres for tissue bulking
EP1267839B1 (de) 2000-03-24 2007-10-03 Biosphere Medical, Inc. Mikrokugeln zur aktiven embolisierung
SE517422C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Farmaceutiskt acceptabel stärkelse
SE517421C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
JP2004510730A (ja) 2000-10-06 2004-04-08 ヤゴテック　アーゲー 非経口的投与可能な制御放出微粒子調製物
WO2002043580A2 (en) 2000-10-27 2002-06-06 Epic Therapeutics, Inc. Production of microspheres
SE518007C2 (sv) 2000-11-16 2002-08-13 Bioglan Ab Förfarande för framställning av mikropartiklar
SE518008C2 (sv) * 2000-11-16 2002-08-13 Bioglan Ab Parenteralt administrerbara mikropartiklar och förfarande för framställning av desamma
US20070142325A1 (en) * 2001-01-08 2007-06-21 Gustavsson Nils O Starch
JP4799749B2 (ja) * 2001-03-29 2011-10-26 花王株式会社 樹脂複合体
JP4206272B2 (ja) * 2001-03-29 2009-01-07 サイナージィ ファーマスーティカルズ、インコーポレイテッド 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト
WO2002100444A1 (en) * 2001-06-08 2002-12-19 Biosphere Medical Inc. Colloidal metal labelled microparticles, their production and use
EP1418890B1 (de) * 2001-08-16 2008-05-14 Baxter International Inc. Darreichungsformen welche mikropartikel und treibgas enthalten
US7105181B2 (en) 2001-10-05 2006-09-12 Jagotec, Ag Microparticles
SE0201599D0 (sv) * 2002-03-21 2002-05-30 Skyepharma Ab Microparticles
US7053134B2 (en) * 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
EP1555938A4 (de) * 2002-06-21 2010-11-03 Reuven Avrahom Cyrulnik System und verfahren für nichtinvasive diagnostische bildgebung, nachweis und identifizierung von substanzen mittels mw/rf-modulation von röntgenstrahlen und anwendungen bei der behandlung von erkrankungen in verbindung mit pathologischen makromolek len oder regenerationsbedarf von normalgewebe
WO2005035088A2 (en) * 2003-07-18 2005-04-21 Baxter International, Inc. Method for preparing small spherical by controlled phase separation
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
JP2007508240A (ja) * 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
US9176121B2 (en) * 2004-02-13 2015-11-03 Roche Diagnostics Hematology, Inc. Identification of blood elements using inverted microscopy
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
EP1753404A1 (de) * 2004-05-12 2007-02-21 Baxter International Inc. Mikrokügelchen mit protein; die bei hohen konzentrationen des mittels injizierbar sind
CA2566079A1 (en) 2004-05-12 2005-12-01 Terrence L. Scott Nucleic acid microspheres, production and delivery thereof
WO2005112885A2 (en) * 2004-05-12 2005-12-01 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
KR20140090270A (ko) 2005-05-09 2014-07-16 바이오스피어 메디칼 에스.에이. 마이크로스피어 및 비이온성 조영제를 사용하는 조성물 및 방법
US8017152B2 (en) * 2005-05-27 2011-09-13 Stratosphere Pharma Ab Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
KR101406415B1 (ko) 2005-07-15 2014-06-19 미셀 테크놀로지즈, 인코포레이티드 제어된 형태의 약물 분말을 함유하는 중합체 코팅
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007038619A2 (en) * 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US20070081972A1 (en) * 2005-09-30 2007-04-12 The University Of Iowa Research Foundation Polymer-based delivery system for immunotherapy of cancer
BRPI0620268B8 (pt) * 2005-12-22 2021-05-25 Oakwood Laboratories LLC composição eficaz como sistema de fornecimento para liberação controlada, seu uso, seu método de fabricação, e método para proteger um agente biologicamente ativo
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
EP1981483A1 (de) * 2006-01-24 2008-10-22 Nexbio, Inc. Technologie für die herstellung von makromolekularen mikrokügelchen
WO2007090130A2 (en) * 2006-01-30 2007-08-09 Surgica Corporation Porous intravascular embolization particles and related methods
US20080033366A1 (en) 2006-01-30 2008-02-07 Surgica Corporation Compressible intravascular embolization particles and related methods and delivery systems
JP2007279028A (ja) * 2006-03-13 2007-10-25 Mitsubishi Chemicals Corp 孔を有する生体物質構造体及びその製造方法、並びに、それを用いた生体物質担持体、対象物質の精製方法、アフィニティークロマトグラフィー用容器、分離用チップ、対象物質の解析方法、対象物質の解析用分離装置、及びセンサーチップ
CA2996768C (en) 2006-04-26 2020-12-08 Micell Technologies, Inc. Coatings containing multiple drugs
EP2647712A3 (de) 2006-08-04 2013-11-20 Baxter International Inc Zusammensetzung auf Mikrokügelchenbasis zur Vorbeugung und/oder Umkehrung einer Neuerkrankung an autoimmun bedingter Diabetes
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
CA2682135A1 (en) 2007-04-17 2008-10-30 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
US20090098110A1 (en) * 2007-05-30 2009-04-16 Duke University Injectable forms of solid-forming crosslinked bioelastic biopolymers for local drug delivery
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
PL2014280T3 (pl) 2007-07-13 2015-04-30 Cc Ery Gmbh Mikrocząsteczki, substytut krwi i sposób ich formowania
MX2010001684A (es) 2007-08-15 2010-04-21 Amunix Inc Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
EP2212412A4 (de) * 2007-10-15 2011-03-09 Biogen Idec Inc Verfahren zur herstellung eines biologikums unter verwendung einer lagerstabilen zwischenverbindung
US8506933B2 (en) * 2007-11-30 2013-08-13 Msdx, Inc. Methods of detecting a neurological condition via analysis of circulating phagocytes
JP5608160B2 (ja) 2008-04-17 2014-10-15 ミセル テクノロジーズ、インコーポレイテッド 生体吸収性の層を有するステント
DK2281042T3 (en) 2008-04-18 2015-11-09 Baxter Int Microsphere-based composition for preventing and / or deletion of starting autoimmune diabetes
BRPI0910850B1 (pt) 2008-04-21 2022-06-14 Otonomy, Inc. Composição intratimpânica compreendendo fator neurotrófico de crescimento derivado do cérebro (bdnf) para o tratamento ou prevenção da perda auditiva
JP2012515931A (ja) 2008-04-25 2012-07-12 ウィンケルマン、ジェイムズ 全血球数及び白血球百分率を決定するシステム及び方法
US9602777B2 (en) 2008-04-25 2017-03-21 Roche Diagnostics Hematology, Inc. Systems and methods for analyzing body fluids
EP2810951B1 (de) * 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
EP2296685B1 (de) * 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
CA2730603C (en) * 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2313122B1 (de) 2008-07-17 2019-03-06 Micell Technologies, Inc. Medizinische wirkstofffreisetzungsvorrichtung
CN102105133B (zh) 2008-07-21 2015-06-17 奥德纳米有限公司 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US20110212179A1 (en) * 2008-10-30 2011-09-01 David Liu Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same
AU2009322285B2 (en) 2008-12-03 2016-07-28 Bausch Health Ireland Limited Formulations of guanylate cyclase C agonists and methods of use
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
JP2012522589A (ja) 2009-04-01 2012-09-27 ミシェル テクノロジーズ，インコーポレイテッド 被覆ステント
EP2453834A4 (de) 2009-07-16 2014-04-16 Micell Technologies Inc Medizinische wirkstofffreisetzungsvorrichtung
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
BR112012009801A8 (pt) 2009-10-30 2016-08-30 Cns Therapeutics Inc Polipeptídeo neurturina e variante de neurturina
WO2011066460A1 (en) * 2009-11-27 2011-06-03 Msdx, Inc. Methods of detecting or monitoring activity of an inflammatory or neurodegenerative condition
EP2531140B1 (de) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent und stenteinsatzsystem mit verbesserter einsetzbarkeit
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
EP2593039B1 (de) 2010-07-16 2022-11-30 Micell Technologies, Inc. Medizinische wirkstofffreisetzungsvorrichtung
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2621509A4 (de) 2010-09-15 2016-08-03 Synergy Pharmaceuticals Inc Formulierungen von guanylatcyclase-c-agonisten und anwendungsverfahren
US9111343B2 (en) 2011-01-18 2015-08-18 Roche Diagnostics Hematology, Inc. Microscope slide coordinate system registration
US8673309B2 (en) 2011-02-11 2014-03-18 Msdx, Inc. Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US9603906B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Inhalable liquid formulations of DNase I
EP2822577B1 (de) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Rekombinante faktor-viii-proteine
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
JP2015527310A (ja) 2012-06-28 2015-09-17 アンサン バイオファーマ, インコーポレイテッドAnsun Biopharma, Inc. 下気道および中枢気道への送達用微粒子製剤ならびに製造方法
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
US20150352050A1 (en) * 2012-11-15 2015-12-10 Utah-Inha Dds & Advanced Therapeutics Research Center Biodegradable microbeads with improved anticancer drug adsorptivity, containing albumin and dextran sulfate, and preparation method therefor
WO2014084530A1 (ko) 2012-11-27 2014-06-05 재단법인 유타 인하 디디에스 및 신의료기술개발공동연구소 음이온성 고분자를 포함하는 항암제 흡착능력이 향상된 생분해성 마이크로 비드 및 이의 제조방법
EP2967803B1 (de) 2013-03-12 2023-12-27 Micell Technologies, Inc. Bioabsorbierbare biomedizinische implantate
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
JP6169255B2 (ja) 2013-05-02 2017-07-26 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ポリアリールエーテルスルホンコポリマー
EP2996629B1 (de) 2013-05-15 2021-09-22 Micell Technologies, Inc. Bioabsorbierbare biomedizinische implantate
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
EP3188716B1 (de) 2014-09-03 2022-10-26 GeneSegues, Inc. Therapeutische nanopartikel und zugehörige zusammensetzungen, verfahren und systeme
WO2016057693A1 (en) 2014-10-10 2016-04-14 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
EP3303585A4 (de) 2015-06-03 2018-10-31 Board of Regents of the University of Nebraska Dna-editierung mit verwendung von einzelstrang-dna
WO2017019907A1 (en) 2015-07-28 2017-02-02 Otonomy, Inc. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
WO2018031771A1 (en) 2016-08-11 2018-02-15 University Of Iowa Research Foundation CATIONIC CaMKII INHIBITING NANOPARTICLES FOR THE TREATMENT OF ALLERGIC ASTHMA
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
CA3087574A1 (en) 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
WO2021076794A1 (en) 2019-10-15 2021-04-22 Cornell University Methods for modulating level of expression from gene therapy expression cassette
US20230405148A1 (en) 2019-10-16 2023-12-21 Cornell University Gene therapy for alzheimer's disease
WO2021086973A2 (en) 2019-10-28 2021-05-06 University Of Iowa Research Foundation Formulation for delivery of lubricin gene
IL293116A (en) 2019-11-25 2022-07-01 Univ Cornell apoe gene therapy
WO2021216547A1 (en) 2020-04-20 2021-10-28 Sorrento Therapeutics, Inc. Pulmonary administration of ace2 polypeptides
CN115835886A (zh) 2020-04-23 2023-03-21 衣阿华大学研究基金会 Gper蛋白水解靶向嵌合体
WO2022040564A1 (en) 2020-08-21 2022-02-24 University Of Iowa Research Foundation Cationic nanoparticle adjuvants
US20230414787A1 (en) 2020-08-27 2023-12-28 University Of Iowa Research Foundation Gene knock-out for treatment of glaucoma
US20240100183A1 (en) 2020-12-11 2024-03-28 University Of Iowa Research Foundation Compositions comprising molecules for cystic fibrosis treatment
WO2022246280A1 (en) 2021-05-21 2022-11-24 University Of Iowa Research Foundation Anti-oxidant containing particles and methods of use
US20240293322A1 (en) 2021-06-23 2024-09-05 University Of Iowa Research Foundation Sustained release formulations comprising a selective androgen receptor modulator
WO2024197165A1 (en) 2023-03-21 2024-09-26 University Of Iowa Research Foundation Broad spectrum antifungal keto-alkyl-pyridinium compounds
WO2024233783A1 (en) 2023-05-09 2024-11-14 Cornell University Expression cassette coding for vascular endothelial growth factor
WO2025213111A2 (en) 2024-04-05 2025-10-09 Cornell University Aav expression of mirna to suppress human apoe mrna

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3137631A (en) * 1959-12-01 1964-06-16 Faberge Inc Encapsulation in natural products
US3663687A (en) * 1968-06-26 1972-05-16 Minnesota Mining & Mfg Biodegradable parenteral microspherules
BE789195A (fr) * 1971-09-24 1973-03-22 Gist Brocades Nv Compositions d'enzymes
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
US4115534A (en) * 1976-08-19 1978-09-19 Minnesota Mining And Manufacturing Company In vitro diagnostic test
US4169804A (en) * 1976-08-19 1979-10-02 Minnesota Mining And Manufacturing Company Magnetically responsive composite microparticle
CH621479A5 (de) * 1977-08-05 1981-02-13 Battelle Memorial Institute
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
JPS5719660A (en) * 1980-07-09 1982-02-01 Fuji Photo Film Co Ltd Microcapsule for immune reaction
JPS5951355A (ja) * 1982-09-17 1984-03-24 Fujirebio Inc 抗ウイルス抗体検出用試薬
US5141738A (en) * 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
US4794000A (en) * 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
SE459005B (sv) * 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
SE462894B (sv) * 1985-10-28 1990-09-17 Biogram Ab Mikrokapslar, foerfarande foer framstaellning daerav samt anvaendning
JPS6317904A (ja) * 1986-07-09 1988-01-25 Mitsubishi Chem Ind Ltd 多孔質架橋ポリビニルアルコ−ル粒子の製造法
JPS6377821A (ja) * 1986-09-19 1988-04-08 Teikoku Seiyaku Kk 安定なプロスタグランジンｅ組成物
IL83451A (en) * 1987-08-06 1991-06-10 Univ Ramot Stabilized water soluble enzymes and a method for their preparation
CA2023803C (en) * 1989-08-23 1999-05-18 Takeshi Miyazaki Method for measuring an immunologically active material and apparatus suitable for practicing said method
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5525519A (en) * 1992-01-07 1996-06-11 Middlesex Sciences, Inc. Method for isolating biomolecules from a biological sample with linear polymers
US6090925A (en) * 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use

Also Published As

Publication number Publication date
EP0688429B1 (de) 1998-02-11
EP0809110A1 (de) 1997-11-26
JP2007212464A (ja) 2007-08-23
DE69433523T2 (de) 2004-12-23
ATE163230T1 (de) 1998-02-15
ES2113094T3 (es) 1998-04-16
JPH08507806A (ja) 1996-08-20
WO1994020856A1 (en) 1994-09-15
US5578709A (en) 1996-11-26
JP2004323528A (ja) 2004-11-18
DK0809110T3 (da) 2004-05-24
DE69433523D1 (de) 2004-03-04
JP2006023297A (ja) 2006-01-26
AU6358594A (en) 1994-09-26
EP0688429A1 (de) 1995-12-27
DE69408527T2 (de) 1998-06-04
DE69408527D1 (de) 1998-03-19
PT809110E (pt) 2004-06-30
JP2007297633A (ja) 2007-11-15
CA2157793C (en) 1999-07-13
CA2157793A1 (en) 1994-09-15
EP0809110B1 (de) 2004-01-28
ES2215207T3 (es) 2004-10-01

Similar Documents

Publication Publication Date Title
DE69433523D1 (de) Makromolekulare Mikropartikel und Verfahren zur ihrer Herstellung
ATE306199T1 (de) Verfahren zur herstellung getrockneter kartoffelflocken
ATE12266T1 (de) Cellulose-form-und-spinnmasse mit geringen anteilen an niedermolekularen abbauprodukten sowie verfahren zur herstellung und verwendung zu formkoerpern.
ATE38841T1 (de) Geformter artikel aus hyaluronsaeure und verfahren zu seiner herstellung.
ZA803599B (en) Method for cross linking polymers,polymer compositions and uses thereof
DE69121605D1 (de) Säure-stabilisiertes Calciumcarbonat, Verfahren zu seiner Herstellung und Anwendungsmethode in der Herstellung von Säure-Papier
ATE173520T1 (de) Papier mit einer beschichtung aus schmelzstabilem polymer und dessen verfahren zur herstellung
CA2161904A1 (en) Polymer Compositions and Their Production, in Particular Absorbent Materials, and Their Use
ATE318848T1 (de) Superabsorbierende gele aus poly(vinylamin) und verfahren zur herstellung davon
ATE193718T1 (de) Schmelzstabile polylactidzusammensetzung
DE69504650D1 (de) Verfahren zur herstellung von wässrigen polymer-zusammensetzungen
DE3668553D1 (de) Waessrige zusammensetzung, verfahren zur herstellung eines wasserabsorbierenden polymers und eines damit ueberzogenen gegenstandes.
ATE78497T1 (de) Verfahren zur herstellung von polymerteilchen, diese polymerteilchen und ihre verwendung.
CS5939290A2 (en) Cross-linked hydrogels, method of their production and their application as wound tegmentum
PT94594A (pt) Processo para a preparacao de composicoes de misturas de base polimerica contendo amido desestruturado
DE59010898D1 (de) Verfahren zur Herstellung von Ethylenpolymeren
DE69004625D1 (de) Verfahren zur Herstellung von strahlungsvernetzbaren Überzügen, strahlungsvernetzbare Zusammensetzungen und Carbonate.
OA06146A (fr) N-phényl-N'-(2'-chloro-6-fluoro-benzoyl)-urées, leur procédé de production et leur application comme insecticides.
DE59008005D1 (de) Verfahren zur Herstellung von hochmolekularen Copolyarylensulfiden.
BR0006288A (pt) Processos de produção para resina absorvente de água básica e agente de absorção de água e uso dos mesmos
DE68916399D1 (de) Lösungsmittelfreier festes Polymerelektrolyt und Verfahren zu seiner Herstellung.
DE59103454D1 (de) Verfahren zur Herstellung von feinteiligen, wasserlöslichen Polymerisaten.
DE69318946D1 (de) Biologisch abbaubares, optisch aktives Lactonpolymer und Verfahren zu seiner Herstellung
ATE22912T1 (de) Durch strahlen vernetzbare zusammensetzung, verfahren zur herstellung und verwendung.
DE69018440D1 (de) Verfahren zur herstellung von hyaluronsäure mit niedrigem molekulargewicht.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0809110

Country of ref document: EP